New class action lawsuit claims Meta's discreet patient data tracker was active across 664 provider websites Lyme-light: Pfizer triggers surge in Valneva’s stock with €91M investment to support phase 3 vaccine trial Human Longevity seeks new life with proposed SPAC deal Novartis' recent Gilenya patent win slips away after appeals court reverses its own prior verdict UnitedHealth unit to pick up UK health tech company EMIS for $1.5B PathAI co-founder Khosla carves a new path as CTO of Iterative Scopes Hot on Alnylam’s heels, AstraZeneca racks up phase 3 win for Ionis-partnered rare disease drug PhRMA says COVID-19 vaccine patent waiver is a 'political stunt,' while advocate argues it doesn't go far enough Supreme Court sides with health plan in payment dispute with dialysis provider DaVita Axcella's CEO knows people are tired of the pandemic. But long COVID patients need help, too Vifor Pharma faces antitrust probe in Europe for allegedly misleading doctors about a rival drug Bioventus reworks $450M CartiHeal acquisition after scrapping original debt financing plan 9 Meters’ celiac drug doesn’t measure up in phase 3 Featured Story | By Dave Muoio After an investigation found Facebook's discreet tracker active among 33 of the top 100 hospitals' online scheduling tools, an anonymous patient is seeking damages on behalf of "millions" of patients whose data was collected by "at least 664 hospital systems or medical provider web properties." read more |
| |
|---|
|
| | L.E.K.’s Looking Ahead 2022 series of Executive Insights looks at how accelerated innovation has brought both unprecedented achievement and enduring challenges for companies throughout the healthcare ecosystem. Click to read more. |
|---|
Top Stories By Nick Paul Taylor Pfizer is throwing its weight behind Valneva to support late-phase development of a Lyme disease vaccine candidate, agreeing to invest $95.6 million as part of a revised deal that triggered an 81% surge in its partner’s share price. read more By Conor Hale Human Longevity, with its goal of helping people live past age 100, has inked a deal with a blank-check company to grab a spot on the New York Stock Exchange and collect $345 million. read more By Fraiser Kansteiner After handing Novartis a win in January, a U.S. appeals court has changed course in a Gilenya patent infringement lawsuit. On Tuesday, the judges revived a Chinese drugmaker’s bid to challenge the blockbuster multiple sclerosis med with its copycat. read more By Heather Landi A UnitedHealth Group unit plans to acquire EMIS Group in an all-cash deal that values the U.K. health technology company at about 1.24 billion pounds sterling, or $1.5 billion, the companies announced Friday. read more By Andrea Park At a fork in the road, Aditya Khosla, Ph.D., is taking the path less traveled: one that will take him away from PathAI, the company he helped start half a decade ago. read more By Nick Paul Taylor AstraZeneca’s $200 million bet on Ionis Pharmaceuticals’ rare disease drug has delivered an early win. A phase 3 trial of eplontersen in hereditary transthyretin-mediated amyloid polyneuropathy hit the mark at an interim analysis, teeing AstraZeneca to make an approval filing that will keep it hot on the heels of Alnylam. read more By Kevin Dunleavy Now that the World Trade Organization has relaxed intellectual property restrictions on COVID-19 vaccines, the question is: Will any developing countries take advantage to produce their own shots? read more By Robert King The Supreme Court struck down a lawsuit filed by DaVita that charged a health plan run by Marietta Memorial Hospital violated federal law by limiting dialysis coverage options. read more By Kevin Dunleavy Visiting Washington, D.C., last week, Axcella CEO Bill Hinshaw is trying to enlist congressional allies to help with long COVID. He’s the first to admit that it’s not an easy sell. read more By Zoey Becker Anticompetitive practices are even more unfair when there's only one competitor. The European Commission opened an investigation of Vifor Pharma's alleged disparagement of competitor Pharmacosmos, whose intravenous treatment might be Vifor's only competition. read more By Andrea Park It’s been a rocky road, but Bioventus is finally back on track to acquire CartiHeal in the coming weeks. read more By Gabrielle Masson 9 Meters Biopharma’s celiac disease drug isn’t measuring up in a phase 3 trial. After an interim analysis found that the study needs an enrollment count that is too large to support continuation, the company is scouring data on sub-groups to see if the therapy may have a treatment effect. read more | 